EVALUATE THE TOLERABILITY OF RIFAXIMIN IN PREVENTING HEPATIC ENCEPHALOPATHY (HE)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 比较在利福昔明550 mg，Bid或安慰剂治疗6个月期间，通过Conn评分和Asterixis分级来衡量先前证实的HE缓解的维持情况。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the maintenance of remission from previously demonstrated HE as measured by Conn score and asterixis grade during 6 months of treatment with rifaximin at 550 mg BID or placebo.